Genprex (GNPX) Competitors $0.24 -0.02 (-6.07%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.25 +0.01 (+3.33%) As of 04/17/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. CARA, GBIO, LEXX, TPST, CGTX, PASG, CYTH, QTTB, DRRX, and KALAShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Cara Therapeutics (CARA), Generation Bio (GBIO), Lexaria Bioscience (LEXX), Tempest Therapeutics (TPST), Cognition Therapeutics (CGTX), Passage Bio (PASG), Cyclo Therapeutics (CYTH), Q32 Bio (QTTB), DURECT (DRRX), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Cara Therapeutics Generation Bio Lexaria Bioscience Tempest Therapeutics Cognition Therapeutics Passage Bio Cyclo Therapeutics Q32 Bio DURECT KALA BIO Cara Therapeutics (NASDAQ:CARA) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment. Which has better earnings & valuation, CARA or GNPX? Genprex has lower revenue, but higher earnings than Cara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara Therapeutics$7.14M0.00-$118.51M-$21.01N/AGenprexN/AN/A-$30.86MN/AN/A Which has more risk & volatility, CARA or GNPX? Cara Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Genprex has a beta of -0.4, meaning that its stock price is 140% less volatile than the S&P 500. Does the MarketBeat Community prefer CARA or GNPX? Cara Therapeutics received 468 more outperform votes than Genprex when rated by MarketBeat users. Likewise, 72.19% of users gave Cara Therapeutics an outperform vote while only 65.25% of users gave Genprex an outperform vote. CompanyUnderperformOutperformCara TherapeuticsOutperform Votes66772.19% Underperform Votes25727.81% GenprexOutperform Votes19965.25% Underperform Votes10634.75% Do analysts prefer CARA or GNPX? Cara Therapeutics currently has a consensus target price of $83.52, suggesting a potential upside of 0.00%. Genprex has a consensus target price of $10.00, suggesting a potential upside of 4,066.67%. Given Genprex's stronger consensus rating and higher possible upside, analysts clearly believe Genprex is more favorable than Cara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Genprex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CARA or GNPX? In the previous week, Cara Therapeutics had 7 more articles in the media than Genprex. MarketBeat recorded 8 mentions for Cara Therapeutics and 1 mentions for Genprex. Genprex's average media sentiment score of 1.00 beat Cara Therapeutics' score of -0.12 indicating that Genprex is being referred to more favorably in the news media. Company Overall Sentiment Cara Therapeutics Neutral Genprex Positive Do insiders and institutionals hold more shares of CARA or GNPX? 44.7% of Cara Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 3.1% of Cara Therapeutics shares are held by company insiders. Comparatively, 8.5% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is CARA or GNPX more profitable? Genprex has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Cara Therapeutics' return on equity of -367.97% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets Cara Therapeutics-1,099.76% -367.97% -107.43% Genprex N/A -409.48%-269.17% SummaryCara Therapeutics beats Genprex on 8 of the 15 factors compared between the two stocks. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.80M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.31%P/E RatioN/A6.9521.9417.82Price / SalesN/A231.01380.9497.68Price / CashN/A65.6738.2634.64Price / Book0.055.936.453.98Net Income-$30.86M$143.22M$3.22B$247.81M7 Day Performance-9.94%4.28%5.85%3.19%1 Month Performance-36.07%-13.11%-9.55%-7.70%1 Year Performance-88.73%-8.51%11.83%1.49% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex4.4093 of 5 stars$0.24-6.1%$10.00+4,066.7%-88.7%$5.80MN/A0.0020Short Interest ↓Positive NewsCARACara Therapeutics3.5483 of 5 stars$5.55+13.3%$27.84+401.6%N/A$25.39M$7.14M-0.2680Stock SplitGap DownGBIOGeneration Bio2.775 of 5 stars$0.37-3.4%$7.33+1,860.8%-86.1%$25.06M$19.89M-0.17150High Trading VolumeLEXXLexaria Bioscience2.3218 of 5 stars$1.41+4.4%$7.00+396.5%-37.3%$24.75M$496,923.00-2.827Earnings ReportShort Interest ↑Positive NewsGap UpTPSTTempest Therapeutics2.4031 of 5 stars$6.96+11.9%$30.00+331.0%-81.9%$24.49MN/A-4.5520CGTXCognition Therapeutics2.5376 of 5 stars$0.39+11.6%$7.13+1,708.4%-79.8%$24.42MN/A-0.4120Gap DownPASGPassage Bio2.4946 of 5 stars$0.38+5.7%$7.50+1,857.7%-71.3%$23.81MN/A-0.33130News CoverageCYTHCyclo Therapeutics2.762 of 5 stars$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809QTTBQ32 Bio1.7956 of 5 stars$1.92-7.7%$24.71+1,187.2%-90.6%$23.42M$-6,651,000.00-0.1339News CoverageDRRXDURECT1.1434 of 5 stars$0.73-2.8%N/A-14.4%$22.60M$2.03M-1.1980Short Interest ↓Positive NewsKALAKALA BIO2.2983 of 5 stars$3.49+3.6%$15.00+329.8%-45.5%$22.52M$3.89M-0.2830 Related Companies and Tools Related Companies CARA Competitors GBIO Competitors LEXX Competitors TPST Competitors CGTX Competitors PASG Competitors CYTH Competitors QTTB Competitors DRRX Competitors KALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
